Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colorectal Neoplasms 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 345Cisplatin 240Paclitaxel 208Radiotherapy 206Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 146Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 101Etoposide 98Bevacizumab 96Specimen Handling 84Nivolumab 77durvalumab 73Radiosurgery 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 44Biopsy 43Irinotecan 42Radiation 41Topotecan 39Standard of Care 38Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × onvansertib × Clear all
NCT05450965 2025-12-17

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

University of Maryland, Baltimore

Phase 2 Recruiting
37 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡